Shandong Luoxin Pharmaceutical Group Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 6,000

Employees

  • Investments
  • 2

  • Share Price
  • $2.11
  • (As of Wednesday Closing)

Shandong Luoxin Pharmaceutical Group General Information

Description

Manufacturer of pharmaceutical products intended for the innovative drug development industry. The company offers tegoprazan tablets, fosaprepitant dimeglumine for injection, ambroxol hydrochloride spray, digestive and respiratory system drugs, anti tumour medications and cardiovascular drugs, thereby enabling healthcare providers to treat medical conditions through pharmaceutical research and freeze dried powder injection technology.

Contact Information

Website
www.luoxin.cn
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Luoqi Road, Linyi National High-tech Industrial Development Zone
  • Linyi, Shandong 200126
  • China
+86 0539
Primary Industry
Pharmaceuticals
Corporate Office
  • Luoqi Road, Linyi National High-tech Industrial Development Zone
  • Linyi, Shandong 200126
  • China
+86 0539

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shandong Luoxin Pharmaceutical Group Stock Performance

As of 31-May-2017, Shandong Luoxin Pharmaceutical Group’s stock price is $2.11. Its current market cap is $1.29B with 610M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.11 $1.52 $1.48 - $2.11 $1.29B 610M 9K $0.97

Shandong Luoxin Pharmaceutical Group Financials Summary

As of 31-Dec-2018, Shandong Luoxin Pharmaceutical Group has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Dec-2018 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017 FY 2016 31-Dec-2016
Revenue 1,400,000 618,697
EBITDA 80,902
Net Income 56,977
Total Assets 629,015
Total Debt 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shandong Luoxin Pharmaceutical Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shandong Luoxin Pharmaceutical Group‘s full profile, request access.

Request a free trial

Shandong Luoxin Pharmaceutical Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of pharmaceutical products intended for the innovative drug development industry. The company offers tegopr
Pharmaceuticals
Linyi, China
6,000 As of 2021

Vienna, Austria
 

Karachi, Pakistan
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shandong Luoxin Pharmaceutical Group Competitors (28)

One of Shandong Luoxin Pharmaceutical Group’s 28 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pfizer (Vienna) Corporation Vienna, Austria
Pfizer Pakistan Corporation Karachi, Pakistan
Evonile Pharma Private Equity-Backed Mumbai, India
Merck & Co. Corporation Rahway, NJ
Genentech Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 28 competitors. Get the full list »

Shandong Luoxin Pharmaceutical Group Patents

Shandong Luoxin Pharmaceutical Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026067510-A1 Tegoprazan injection and preparation method therefor Pending 29-Sep-2024
WO-2026051923-A1 Tegoprazan pyroglutamate injection and preparation method therefor Pending 04-Sep-2024
WO-2022016420-A1 Quinazolinone compound crystal form, preparation method therefor, and use thereof Inactive 22-Jul-2020
WO-2021047466-A1 Crystal form of p53-mdm2 inhibitor and preparation method therefor Inactive 12-Sep-2019
WO-2021042890-A1 Heterocyclic compound and application thereof as trk kinase inhibitor Inactive 04-Sep-2019
To view Shandong Luoxin Pharmaceutical Group’s complete patent history, request access »

Shandong Luoxin Pharmaceutical Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shandong Luoxin Pharmaceutical Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Shandong Luoxin Pharmaceutical Group‘s full profile, request access.

Request a free trial

Shandong Luoxin Pharmaceutical Group Investments (2)

Shandong Luoxin Pharmaceutical Group’s most recent deal was a Corporate with Luoxin Health Technology for . The deal was made on 20-Apr-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Luoxin Health Technology 20-Apr-2022 Corporate Medical Supplies
Luoxin Aurovitas Pharma 25-Mar-2019 Joint Venture Medical Supplies
To view Shandong Luoxin Pharmaceutical Group’s complete investments history, request access »

Shandong Luoxin Pharmaceutical Group Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Luoxin Health Technology Beijing, China 2020

Shandong Luoxin Pharmaceutical Group FAQs

  • When was Shandong Luoxin Pharmaceutical Group founded?

    Shandong Luoxin Pharmaceutical Group was founded in 1996.

  • Where is Shandong Luoxin Pharmaceutical Group headquartered?

    Shandong Luoxin Pharmaceutical Group is headquartered in Linyi, China.

  • What is the size of Shandong Luoxin Pharmaceutical Group?

    Shandong Luoxin Pharmaceutical Group has 6,000 total employees.

  • What industry is Shandong Luoxin Pharmaceutical Group in?

    Shandong Luoxin Pharmaceutical Group’s primary industry is Pharmaceuticals.

  • Is Shandong Luoxin Pharmaceutical Group a private or public company?

    Shandong Luoxin Pharmaceutical Group is a Public company.

  • What is the current stock price of Shandong Luoxin Pharmaceutical Group?

    As of 31-May-2017 the stock price of Shandong Luoxin Pharmaceutical Group is $2.11.

  • What is the current market cap of Shandong Luoxin Pharmaceutical Group?

    The current market capitalization of Shandong Luoxin Pharmaceutical Group is $1.29B.

  • Who are Shandong Luoxin Pharmaceutical Group’s competitors?

    Pfizer (Vienna), Pfizer Pakistan, Evonile Pharma, Merck & Co., and Genentech are some of the 28 competitors of Shandong Luoxin Pharmaceutical Group.

  • What is Shandong Luoxin Pharmaceutical Group’s annual earnings per share (EPS)?

    Shandong Luoxin Pharmaceutical Group’s EPS for 12 months was $0.97.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process